Mabylon Secures €31.8M for Allergy Antibody Breakthrough
August 13, 2025, 3:32 am
Location: United States, California, South San Francisco
Employees: 10001+
Founded date: 1896
Swiss biotech innovator Mabylon secured €31.8 million in crucial funding. This capital boost propels its human-derived antibody platform forward. The primary focus is advancing MY006, a tri-specific antibody for severe peanut allergy, into pivotal clinical trials by 2027. Funds also accelerate pre-clinical programs for major birch and grass pollen allergies. This significant investment validates Mabylon's unique scientific approach. It targets high unmet medical needs globally. The move reinforces confidence despite a challenging worldwide funding environment. Dr. Thomas Hecht joins the Board of Directors, strengthening leadership. This marks a critical step for precision allergy treatment and medical innovation.
The biotech landscape buzzes with innovation. Swiss firm Mabylon leads a new charge. It recently announced a substantial financial close. This infusion fuels its advanced antibody therapies. The company aims to redefine allergy treatment. Its focus on human-derived antibodies promises a novel approach.
Mabylon raised €31.8 million. This capital comes from a combined financing round. It includes a capital increase. It also features a convertible loan. Each component contributed €15.9 million. Existing private investors backed the round. Former management and board members from Roche provided major investment. This signals strong industry confidence in Mabylon's work. The funding supports ambitious development timelines for its key programs.
Mabylon harnesses naturally occurring human antibodies. This is a core differentiator. The company believes human-derived antibodies offer superior therapeutic potential. They outperform antibodies from conventional sources. These include humanized animal models. They also surpass artificial libraries. Mabylon's antibodies come from allergic patients. They precisely target disease-relevant epitopes. This expands understanding of allergenic pathways. It provides a novel therapeutic avenue. The approach targets specific disease progression mechanisms, offering a more precise treatment.
The lead program is MY006. It is a tri-specific antibody. MY006 neutralizes peanut allergens. Peanut allergy represents a significant unmet medical need. Current treatments often manage symptoms. They do not cure the condition. Mabylon will advance MY006 to Phase Ia/b trials. The trial completion is targeted for 2027. Robust safety data is a key goal. Preliminary efficacy data will also emerge. This moves closer to a clinical proof-of-concept for the innovative treatment.
Beyond peanut allergy, Mabylon’s pipeline expands. The funding supports other discovery programs. MY010 is one such candidate. It is a multi-specific and cross-reactive antibody. MY010 targets the birch Bet v 1 allergen. It also addresses major birch-related tree, fruit, and nut allergens. This broadens its therapeutic reach for common airborne allergies. Another product, MY011, targets grass pollen allergies. These conditions affect millions globally. Mabylon's growing portfolio addresses diverse allergic conditions with targeted solutions.
Allergies are a growing public health concern. Millions suffer from severe reactions. Food allergies can be life-threatening. Environmental allergies impact quality of life. Current treatments often involve avoidance or symptomatic relief. Immunotherapy exists but can be lengthy. It also carries risks. There is a pressing demand for safer, more effective solutions. Mabylon’s antibody platform offers a promising alternative. Its precision approach targets root causes. This could revolutionize long-term allergy management.
Mabylon's governance also saw changes. Dr. Thomas Hecht joined the Board of Directors. He brings extensive industry expertise. His appointment strengthens the company's strategic direction. Dr. Hecht succeeds Prof. Adriano Aguzzi. This leadership transition aims to accelerate pipeline commercialization. Strong leadership is vital for biotech success. It ensures continued progress towards medical breakthroughs.
Securing significant capital is challenging. The global funding environment remains tight. This investment highlights Mabylon's strong value proposition. Investors recognize the potential of human-derived antibodies. They see the vast market for allergy therapies. Roche-affiliated investment adds further credibility. It underscores the scientific merit of Mabylon's platform. This funding positions Mabylon for accelerated growth in a competitive landscape.
Mabylon’s work extends beyond allergies. The company explores applications in neurodegenerative diseases. It also investigates inflammatory conditions. This highlights the platform’s versatility. The immediate focus remains allergy treatment. Success in these trials could transform patient care. It offers hope for long-term solutions, moving beyond symptom management. Mabylon aims to establish a new standard. It seeks to deliver best-in-class allergen-neutralizing antibodies. The path to clinical proof-of-concept is now clear. This Swiss biotech is one to watch. Its innovative approach promises significant medical advancements.
The biotech landscape buzzes with innovation. Swiss firm Mabylon leads a new charge. It recently announced a substantial financial close. This infusion fuels its advanced antibody therapies. The company aims to redefine allergy treatment. Its focus on human-derived antibodies promises a novel approach.
Mabylon raised €31.8 million. This capital comes from a combined financing round. It includes a capital increase. It also features a convertible loan. Each component contributed €15.9 million. Existing private investors backed the round. Former management and board members from Roche provided major investment. This signals strong industry confidence in Mabylon's work. The funding supports ambitious development timelines for its key programs.
Mabylon harnesses naturally occurring human antibodies. This is a core differentiator. The company believes human-derived antibodies offer superior therapeutic potential. They outperform antibodies from conventional sources. These include humanized animal models. They also surpass artificial libraries. Mabylon's antibodies come from allergic patients. They precisely target disease-relevant epitopes. This expands understanding of allergenic pathways. It provides a novel therapeutic avenue. The approach targets specific disease progression mechanisms, offering a more precise treatment.
The lead program is MY006. It is a tri-specific antibody. MY006 neutralizes peanut allergens. Peanut allergy represents a significant unmet medical need. Current treatments often manage symptoms. They do not cure the condition. Mabylon will advance MY006 to Phase Ia/b trials. The trial completion is targeted for 2027. Robust safety data is a key goal. Preliminary efficacy data will also emerge. This moves closer to a clinical proof-of-concept for the innovative treatment.
Beyond peanut allergy, Mabylon’s pipeline expands. The funding supports other discovery programs. MY010 is one such candidate. It is a multi-specific and cross-reactive antibody. MY010 targets the birch Bet v 1 allergen. It also addresses major birch-related tree, fruit, and nut allergens. This broadens its therapeutic reach for common airborne allergies. Another product, MY011, targets grass pollen allergies. These conditions affect millions globally. Mabylon's growing portfolio addresses diverse allergic conditions with targeted solutions.
Allergies are a growing public health concern. Millions suffer from severe reactions. Food allergies can be life-threatening. Environmental allergies impact quality of life. Current treatments often involve avoidance or symptomatic relief. Immunotherapy exists but can be lengthy. It also carries risks. There is a pressing demand for safer, more effective solutions. Mabylon’s antibody platform offers a promising alternative. Its precision approach targets root causes. This could revolutionize long-term allergy management.
Mabylon's governance also saw changes. Dr. Thomas Hecht joined the Board of Directors. He brings extensive industry expertise. His appointment strengthens the company's strategic direction. Dr. Hecht succeeds Prof. Adriano Aguzzi. This leadership transition aims to accelerate pipeline commercialization. Strong leadership is vital for biotech success. It ensures continued progress towards medical breakthroughs.
Securing significant capital is challenging. The global funding environment remains tight. This investment highlights Mabylon's strong value proposition. Investors recognize the potential of human-derived antibodies. They see the vast market for allergy therapies. Roche-affiliated investment adds further credibility. It underscores the scientific merit of Mabylon's platform. This funding positions Mabylon for accelerated growth in a competitive landscape.
Mabylon’s work extends beyond allergies. The company explores applications in neurodegenerative diseases. It also investigates inflammatory conditions. This highlights the platform’s versatility. The immediate focus remains allergy treatment. Success in these trials could transform patient care. It offers hope for long-term solutions, moving beyond symptom management. Mabylon aims to establish a new standard. It seeks to deliver best-in-class allergen-neutralizing antibodies. The path to clinical proof-of-concept is now clear. This Swiss biotech is one to watch. Its innovative approach promises significant medical advancements.